Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iREC-MAC intermittent vs daily therapy for noncavitary nodular bronchiectatic MAC lung disease
jRCTs031190008Completed
- Sponsor
- National Hospital Organization
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clarithromycin, ethambutol and rifampicin in Mycobacterium avium-intracellulare infection (MAI) (2 arms), sponsored by National Hospital Organization. Primary endpoint: Primary regimen modification. Started May 2019; status: completed.
02
Drugs
clarithromycinethambutolrifampicin
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on jRCTs031190008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190008.